Chugai Pharmaceutical Co., Ltd. (4519.T) JPX
Currency In JPY
- General
- Statistics
- Historical Data
- Profile
- Financials
Chugai Pharmaceutical Co., Ltd.
Address
Nihonbashi Mitsui Tower
Tokyo, 103-8324
Japan
Phone
81 3 3281 6611
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
7872
First IPO Date
March 02, 1956
Key Executives
| Name | Title | Pay | Year Born |
| Osamu Okuda | President, Chief Executive Officer & Chairman | 272M | 1963 |
| Tomoyuki Igawa | Vice President & Head of Research Division | 0 | N/A |
| Nobuya Ishii | Head of Science & Technology Intelligence Dept. | 0 | N/A |
| Shinya Takuma | VP & Head of Manufacturing Technology Division | 0 | N/A |
| Kosuke Iijima | Head of PHC Solution Department | 0 | N/A |
| Iwaaki Taniguchi | Senior Executive Officer, CFO, Head of Finance & Director | 0 | 1966 |
| Shinji Hidaka | Executive Vice President | 0 | N/A |
| Toshiya Sasai | Executive of Investor Relations Group & Corporate Communications Department | 0 | N/A |
| Junichi Takano | Head of Marketing & Sales Division | 0 | N/A |
| Yoshiyuki Yano | Executive Vice President | 0 | N/A |
| Kaori Ouchi | Executive Vice President | 0 | N/A |
| Tetsuya Yamaguchi | Executive Vice President | 0 | N/A |
Description
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
